Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors
- 236 Downloads
The γ-irradiation of normal cells causes an increased synthesis of specific proteins. However, few studies have described the effects of high doses of irradiation on the expression of cell surface antigens in tumor cells. This study analyzed the effects of high doses of γ-irradiation on the surface antigen expression of Major Histocompatability Complex (MHC) class I/II and intercellular adhesion molecule-1 (ICAM-I) in human multiple myeloma (MM) cell lines ARP-1, ARK-RS, and 10 MM primary tumors. The expression of surface antigens was evaluated by fluorescence-activated cell sorter analysis at different time points, following the exposure to high doses of γ-irradiation. Doses of 10,000 and 15,000 cGy were no0105 sufficient to totally block cell replication in both cell lines and primary tumors; cell replication was able to be inhibited completely only at 18,000 cGy. Lower doses (10,000 cGy) and lethal doses of irradiation (i.e., 15,000 and 18,000 cGy) increased the expression of all surface antigens present on the cells before irradiation. Essentially, such upregulation was shown to be dose dependent, with higher radiation doses resulting in higher antigen expression. Furthermore, when the kinetics of this upregulation were studied 3 and 6 d after irradiation, there was a constant increase in antigen expression in MM cells. These findings suggest that upregulation of costimulatory molecules, such as of MHC class I/II antigens and ICAM-1 molecules in MM patients treated by γ-radiation, can increase the immunogenicity of the tumor cells. In light of these findings, radiotherapy combined with immunotherapy might be considered in relapsing patients after receiving the standard treatment.
Key wordsmultiple myeloma tumor MHC gamma irradiation radiotherapy
Unable to display preview. Download preview PDF.
- Dranoff, G.; Jaffee, E.; Lazenby, A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long&hyhen→sting anti-tumor immunity. Proc Natl Acad. Sci. USA 90:3539–3543; 1993.PubMedCrossRefGoogle Scholar
- Hall E. J. Time, dose, and fractionation in radiotherapy. In: Radiobiology for the Radiologist, 3nd ed. Philadelphia, PA: J B. Lippincott Company; 1988:239–259.Google Scholar
- Harousseau, J. L.; Attal, M.; Divine, M., et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 2:129–132; 1995.Google Scholar
- Tricot, G.; Barlogie, B.; Jagannath, S. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 11:4250–4256; 1995.Google Scholar
- van Seventer, G. A.; Bovini, E.; Yamada, H., et al. Costimulation of T-cell receptor/CD3-mediated activation of resting human CD4+ T-cells by leukocyte function-associated antigen-1 ligand intercellular cell adhesion molecule-1 involves prolonged inositol phospholipid hydrolysis and sustained increase of intracellular Ca2+ levels. J. Immunol 149:3872–3880; 1992.PubMedGoogle Scholar